Antipsychotic-induced hyperprolactinaemia
- PMID: 21714721
- DOI: 10.3109/00048674.2011.589044
Antipsychotic-induced hyperprolactinaemia
Abstract
Background and objectives: Antipsychotic medications are a potential cause of hyperprolactinaemia and may be implicated in the development of pituitary adenomas. This review examines the effect of different antipsychotic medications on prolactin and sexual function, and provides practical guidelines for investigation and management of antipsychotic-induced hyperprolactinaemia.
Method: Literature review.
Results and conclusions: Antipsychotic-induced hyperprolactinaemia occurs overall in up to 70% of patients with schizophrenia, depending on the medications used. It is associated with significant levels of hypogonadism and sexual dysfunction, which in general relates to the degree of prolactin elevation. A consequence of the hypogonadism is clinically significant bone loss which may lead to osteoporosis and increased risk of minimal trauma fracture. Where the potentially offending drug cannot be safely withdrawn to document a normal prolactin, imaging with MRI should be undertaken to exclude a structural pituitary lesion. The management strategy of choice is switching to a prolactin-sparing antipsychotic. Sex steroid replacement can reverse many of the adverse effects including the hypogonadal symptoms and bone loss. Low dose dopamine agonist therapy should be used with caution as a third line treatment, since there have been cases of dopamine agonist-induced exacerbation of psychosis. There is a need for a randomised controlled trial of low dose dopamine agonist therapy versus sex steroid replacement to establish the relative safety and efficacy of each approach.
Similar articles
-
Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.J Psychopharmacol. 2008 Mar;22(2 Suppl):70-5. doi: 10.1177/0269881107088439. J Psychopharmacol. 2008. PMID: 18477623 Review.
-
Hyperprolactinaemia and antipsychotic therapy in schizophrenia.Curr Med Res Opin. 2004;20(2):189-97. doi: 10.1185/030079903125002865. Curr Med Res Opin. 2004. PMID: 15006013 Review.
-
[Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].Neuropsychiatr. 2009;23(2):71-83. Neuropsychiatr. 2009. PMID: 19573500 German.
-
[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5. Encephale. 2014. PMID: 23928066 Review. French.
-
Antipsychotic-induced hyperprolactinemia and sexual dysfunction.Psychopharmacol Bull. 2002 Winter;36(1):143-64. Psychopharmacol Bull. 2002. PMID: 12397853 Review.
Cited by
-
Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse.Clin Psychopharmacol Neurosci. 2023 Nov 30;21(4):769-777. doi: 10.9758/cpn.23.1057. Epub 2023 Jun 7. Clin Psychopharmacol Neurosci. 2023. PMID: 37859450 Free PMC article.
-
Development of a Guideline for Antipsychotic-induced Hyperprolactinemia in Korea Using the ADAPTE Process.Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):447-456. doi: 10.9758/cpn.22.979. Clin Psychopharmacol Neurosci. 2023. PMID: 37424413 Free PMC article.
-
Treatment of Prolactinoma.Medicina (Kaunas). 2022 Aug 13;58(8):1095. doi: 10.3390/medicina58081095. Medicina (Kaunas). 2022. PMID: 36013562 Free PMC article. Review.
-
Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.Transl Psychiatry. 2022 Jul 5;12(1):267. doi: 10.1038/s41398-022-02027-4. Transl Psychiatry. 2022. PMID: 35790713 Free PMC article.
-
Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial.Front Mol Neurosci. 2022 May 26;15:892477. doi: 10.3389/fnmol.2022.892477. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35721320 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical